Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of an overhaul of its business and pipeline that’s expected to ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) (“Sage”) on behalf of the company’s long-term investors.

NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...